B. Crépon

DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.

J. Herbert, J. Hérault, J. Lormeau, 1996, The Journal of pharmacology and experimental therapeutics.

Molecular weight dependency of the acquired anticomplementary and anticoagulant activities of specifically substituted dextrans.

M. Kazatchkine, J. Jozefonvicz, B. Crépon, 1987, Biomaterials.

Antithrombotic activity, bleeding effect and pharmacodynamics of a succinyl derivative of dermatan sulphate in rabbits

G. Houin, B. Boneu, M. Petitou, 1992, British journal of haematology.

Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).

J. Herbert, J. Hérault, M. Petitou, 1997, Journal of medicinal chemistry.

Pharmacokinetic study of three synthetic AT‐binding pentasaccharides in various animal species‐extrapolation to humans

J. Herbert, J. Hérault, J. Lormeau, 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Enzymatic degradation and immunogenic properties of derivatized dextrans.

B. Říhová, J. Kopeček, J Kopecek, 1991, Biomaterials.

Pharmacological Properties of CY 216 and of Its ACLM and BCLM Components in the Rabbit

G. Houin, B. Boneu, S. Salvin, 1994, Thrombosis and Haemostasis.